Literature DB >> 12797118

Antisense downregulation of mutant huntingtin in a cell model.

Lis Hasholt1, Kathrine Abell, Anne Nørremølle, Christine Nellemann, Kirsten Fenger, Sven Asger Sørensen.   

Abstract

BACKGROUND: Huntington's disease (HD) is an inherited neurodegenerative disorder which is caused by an expansion of a CAG repeat sequence in the HD gene. The repeat encodes an expanded polyglutamine tract in the protein huntingtin. The still unknown pathological mechanisms leading to death of specific neurons in the brains of HD patients correlate with the expression of mutant huntingtin. Therefore, we have studied whether mutant huntingtin expression can be downregulated by antisense technique.
METHODS: NT2 precursor cells and differentiated postmitotic NT2-N neurons, respectively, were transfected with plasmid constructs containing exon 1 of the HD gene with expanded CAG repeats in frame with the reporter protein EGFP. The transfected cell cultures were treated with a phosphorothioated antisense oligonucleotide (PS-ASHD/20+) or a control oligonucleotide either by cotransfection or by addition to the culture medium.
RESULTS: Expression of the fusion protein containing the mutant huntingtin fragment resulted in diffuse green fluorescence in the cytoplasm and formation of aggregates in some of the NT2 cells and NT2-N neurons. We obtained antisense sequence-specific inhibition of expression of the fusion protein and/or suppression of the aggregate formation in both cell types. In the NT2 cells the antisense effect was dependent on the way of administration of the oligo.
CONCLUSIONS: The PS-antisense oligo is effective in downregulation of mutant huntingtin, and the reduction of aggregate formation is a sensitive biological marker. The findings suggest that antisense knockdown of huntingtin could be a useful strategy for treatment of HD, and could also be suitable for studies of the normal and pathological function of huntingtin in different cellular model systems. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797118     DOI: 10.1002/jgm.378

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  7 in total

Review 1.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  Tubulin polymerization-promoting protein (TPPP/p25α) promotes unconventional secretion of α-synuclein through exophagy by impairing autophagosome-lysosome fusion.

Authors:  Patrick Ejlerskov; Izabela Rasmussen; Troels Tolstrup Nielsen; Ann-Louise Bergström; Yumi Tohyama; Poul Henning Jensen; Frederik Vilhardt
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

3.  Mutations in HSPB8 causing a new phenotype of distal myopathy and motor neuropathy.

Authors:  Roula Ghaoui; Johanna Palmio; Janice Brewer; Monkol Lek; Merrilee Needham; Anni Evilä; Peter Hackman; Per-Harald Jonson; Sini Penttilä; Anna Vihola; Sanna Huovinen; Mikaela Lindfors; Ryan L Davis; Leigh Waddell; Simran Kaur; Con Yiannikas; Kathryn North; Nigel Clarke; Daniel G MacArthur; Carolyn M Sue; Bjarne Udd
Journal:  Neurology       Date:  2015-12-30       Impact factor: 9.910

4.  Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.

Authors:  Jiaxin Hu; Masayuki Matsui; David R Corey
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

5.  PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons.

Authors:  Przemyslaw Wareski; Annika Vaarmann; Vinay Choubey; Dzhamilja Safiulina; Joanna Liiv; Malle Kuum; Allen Kaasik
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

6.  Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy.

Authors:  Jaakko Sarparanta; Per Harald Jonson; Christelle Golzio; Satu Sandell; Helena Luque; Mark Screen; Kristin McDonald; Jeffrey M Stajich; Ibrahim Mahjneh; Anna Vihola; Olayinka Raheem; Sini Penttilä; Sara Lehtinen; Sanna Huovinen; Johanna Palmio; Giorgio Tasca; Enzo Ricci; Peter Hackman; Michael Hauser; Nicholas Katsanis; Bjarne Udd
Journal:  Nat Genet       Date:  2012-02-26       Impact factor: 38.330

7.  The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer.

Authors:  Eric T Shinohara; Dennis E Hallahan; Bo Lu
Journal:  Biol Proced Online       Date:  2004-10-25       Impact factor: 3.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.